Zenas BioPharma Past Earnings Performance
Past criteria checks 0/6
Zenas BioPharma's earnings have been declining at an average annual rate of -309%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-309.0%
Earnings growth rate
-100.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -35.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Zenas BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -129 | 23 | 0 |
| 30 Jun 24 | 50 | -55 | 20 | 0 |
| 31 Mar 24 | 50 | -46 | 18 | 0 |
| 31 Dec 23 | 50 | -37 | 17 | 0 |
| 30 Sep 23 | 50 | -32 | 16 | 0 |
Quality Earnings: ZBIO is currently unprofitable.
Growing Profit Margin: ZBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ZBIO's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ZBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ZBIO has a negative Return on Equity (-35.88%), as it is currently unprofitable.